Compounds > 4,5-dimethoxy-2-nitrobenzaldehyde
Page last updated: 2024-11-06

4,5-dimethoxy-2-nitrobenzaldehyde

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID88505
CHEMBL ID1332518
CHEBI ID108597
SCHEMBL ID211200
MeSH IDM0559467

Synonyms (57)

Synonym
AC-4248
HMS3268J17
BRD-K03564313-001-02-5
6-nitroveratraldehyde
3,4-dimethoxy-6-nitrobenzaldehyde
2-nitro-4,5-dimethoxybenzaldehyde
2-nitro-4,5-bis(methyloxy)benzaldehyde
AE-641/30608009
nsc65590
nsc-65590
HSCI1_000095
4,5-dimethoxy-2-nitrobenzaldehyde
benzaldehyde, 4,5-dimethoxy-2-nitro-
20357-25-9
inchi=1/c9h9no5/c1-14-8-3-6(5-11)7(10(12)13)4-9(8)15-2/h3-5h,1-2h
6-nitroveratraldehyde, technical grade, 80%
dmnb
NCGC00092305-01
OPREA1_551791
CHEBI:108597
AKOS000100856
N0538
ST044482
6-nitro veratraldehyde
STK361573
A814482
4,5-dimethoxy-2-nitro-benzaldehyde
3v2svj99e2 ,
nsc 65590
einecs 243-762-1
unii-3v2svj99e2
bdbm50398040
chembl1332518 ,
BP-12518
FT-0621281
S5510
SCHEMBL211200
TD1274
W-107627
STR05106
4,5-dimethoxy-2-nitrobenzaldehyde #
Q27187519
DTXSID30174268
mfcd00007134
CS-D1696
BBL104434
SY023985
dna-pk inhibitor - cas 20357-25-9
HMS3677E15
HMS3413E15
dmnb4,5-dimethoxy-2-nitrobenzaldehyde
CCG-266652
HY-100705
EN300-18321
veratraldehyde, 6-nitro-
Z57888147
AKOS040759472
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (26)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.17780.003245.467312,589.2998AID2517
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency5.00000.140911.194039.8107AID2451
Chain A, HADH2 proteinHomo sapiens (human)Potency15.84890.025120.237639.8107AID886
Chain B, HADH2 proteinHomo sapiens (human)Potency15.84890.025120.237639.8107AID886
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency10.00000.177814.390939.8107AID2147
15-lipoxygenase, partialHomo sapiens (human)Potency39.81070.012610.691788.5700AID887
Microtubule-associated protein tauHomo sapiens (human)Potency4.73590.180013.557439.8107AID1460; AID1468
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency11.22020.011212.4002100.0000AID1030
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency25.11890.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA-dependent protein kinase catalytic subunitHomo sapiens (human)IC50 (µMol)15.00000.00051.350010.0000AID705446
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (46)

Processvia Protein(s)Taxonomy
peptidyl-serine phosphorylationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
maturation of 5.8S rRNADNA-dependent protein kinase catalytic subunitHomo sapiens (human)
somitogenesisDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
negative regulation of protein phosphorylationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
activation of innate immune responseDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
B cell lineage commitmentDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
immature B cell differentiationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
pro-B cell differentiationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
T cell lineage commitmentDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
double-strand break repairDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
double-strand break repair via nonhomologous end joiningDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
chromatin remodelingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein phosphorylationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
DNA damage responseDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
brain developmentDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
heart developmentDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
response to gamma radiationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
telomere cappingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
peptidyl-serine phosphorylationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
peptidyl-threonine phosphorylationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
mitotic G1 DNA damage checkpoint signalingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein destabilizationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
cellular response to insulin stimulusDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
T cell differentiation in thymusDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
T cell receptor V(D)J recombinationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
small-subunit processome assemblyDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
ectopic germ cell programmed cell deathDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein modification processDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
regulation of circadian rhythmDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of apoptotic processDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
negative regulation of apoptotic processDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
innate immune responseDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of lymphocyte differentiationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of erythrocyte differentiationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of translationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
rhythmic processDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
regulation of smooth muscle cell proliferationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
regulation of epithelial cell proliferationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
double-strand break repair via alternative nonhomologous end joiningDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
negative regulation of cGAS/STING signaling pathwayDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
regulation of hematopoietic stem cell differentiationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of platelet formationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of double-strand break repair via nonhomologous end joiningDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
immunoglobulin V(D)J recombinationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
telomere maintenanceDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (13)

Processvia Protein(s)Taxonomy
double-stranded DNA bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
RNA bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein kinase activityDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein serine/threonine kinase activityDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
DNA-dependent protein kinase activityDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
ATP bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
enzyme bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein domain specific bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
U3 snoRNA bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
histone H2AXS139 kinase activityDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein serine kinase activityDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (15)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
chromosome, telomeric regionDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
nucleusDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
nucleoplasmDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
nucleolusDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
cytosolDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
membraneDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
DNA-dependent protein kinase complexDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
chromatinDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
transcription regulator complexDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
DNA-dependent protein kinase-DNA ligase 4 complexDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
small-subunit processomeDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein-containing complexDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein-DNA complexDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
nonhomologous end joining complexDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
nucleusDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1524436Substrate activity at recombinant Haemophilus influenzae Chloramphenicol nitroreductase expressed in Escherichia coli assessed as initial rate of reaction at 150 uM measured at 30 sec interval for 5 mins in presence of NADPH at pH 8 under 37 degC by UV-vi2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
Investigating the promiscuity of the chloramphenicol nitroreductase from Haemophilus influenzae towards the reduction of 4-nitrobenzene derivatives.
AID705446Inhibition of DNA-PK assessed as inhibition of p53 peptide phosphorylation2012Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (71.43)24.3611
2020's2 (28.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.48

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.48 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.48)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (14.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
4-nitrobenzaldehyde
4-nitrobenzaldehyde: RN given refers to parent cpd. 4-nitrobenzaldehyde : A C-nitro compound that is benzaldehyde substituted at the para-position with a nitro group.		2.2110benzaldehydes;
C-nitro compound
4-nitrophenol
4-nitrophenol: RN given refers to parent cpd. mononitrophenol : A nitrophenol that is phenol carrying a single nitro substituent at unspecified position.. 4-nitrophenol : A member of the class of 4-nitrophenols that is phenol in which the hydrogen that is para to the hydroxy group has been replaced by a nitro group.		2.21104-nitrophenolshuman xenobiotic metabolite;
mouse metabolite
vanillin
Vanilla: A plant genus of the family ORCHIDACEAE that is the source of the familiar flavoring used in foods and medicines (FLAVORING AGENTS).		3.1710benzaldehydes;
monomethoxybenzene;
phenols		anti-inflammatory agent;
anticonvulsant;
antioxidant;
flavouring agent;
plant metabolite
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source		3.1710chromones;
morpholines;
organochlorine compound		autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector
trifluoperazine
[no description available]		3.1710N-alkylpiperazine;
N-methylpiperazine;
organofluorine compound;
phenothiazines		antiemetic;
calmodulin antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor;
phenothiazine antipsychotic drug
chloramphenicol
Amphenicol: Chloramphenicol and its derivatives.		2.2110C-nitro compound;
carboxamide;
diol;
organochlorine compound		antibacterial drug;
antimicrobial agent;
Escherichia coli metabolite;
geroprotector;
Mycoplasma genitalium metabolite;
protein synthesis inhibitor
dithionitrobenzoic acid
Dithionitrobenzoic Acid: A standard reagent for the determination of reactive sulfhydryl groups by absorbance measurements. It is used primarily for the determination of sulfhydryl and disulfide groups in proteins. The color produced is due to the formation of a thio anion, 3-carboxyl-4-nitrothiophenolate.. dithionitrobenzoic acid : An organic disulfide that results from the formal oxidative dimerisation of 2-nitro-5-thiobenzoic acid. An indicator used to quantify the number or concentration of thiol groups.		2.2110nitrobenzoic acid;
organic disulfide		indicator
nitrobenzene
nitrobenzene : A nitroarene consisting of benzene carrying a single nitro substituent. An industrial chemical used widely in the production of aniline.		2.2110nitroarene;
nitrobenzenes
1,2-dichloro-4-nitrobenzene
[no description available]		2.2110
4-nitroaniline
[no description available]		2.2110nitroanilinebacterial xenobiotic metabolite
2-nitrobenzaldehyde
2-nitrobenzaldehyde: structure given in first source. 2-nitrobenzaldehyde : Benzaldehyde substituted at the ortho-position with a nitro group.		2.2110benzaldehydes;
C-nitro compound
nitrohexane
nitrohexane: formed by deliberate nitrosation of corn; RN given refers to cpd with unspecified nitro locant; RN & N1 from 9th CI Form Index. 1-nitrohexane : A primary nitroalkane that is hexane substituted by a nitro group at position 1.		2.2110primary nitroalkanehuman urinary metabolite
methylnitrosourea
Methylnitrosourea: A nitrosourea compound with alkylating, carcinogenic, and mutagenic properties.. N-methyl-N-nitrosourea : A member of the class of N-nitrosoureas that is urea in which one of the nitrogens is substituted by methyl and nitroso groups.		2.1510N-nitrosoureasalkylating agent;
carcinogenic agent;
mutagen;
teratogenic agent
nsc 520594
[no description available]		2.2110
4-nitrobenzyl bromide
4-nitrobenzyl bromide: structure given in first source. 4-nitrobenzyl bromide : A C-nitro compound that consists of nitrobenzene bearing a bromomethyl substituent at the para-position.		2.2110benzyl bromides;
C-nitro compound		allergen;
sensitiser
4-nitrobenzyl alcohol
4-nitrobenzyl alcohol : A member of the class of benzyl alcohols that is benzyl alcohol substituted at the para-position by a nitro group.		2.2110benzyl alcohols;
C-nitro compound		xenobiotic metabolite
4-nitropyridine
[no description available]		2.2110
4-nitrophenyl butyrate
p-nitrophenyl butyrate : A butyrate ester resulting from the formal condensation of the hydroxy group of 4-nitrophenol with the carboxy group of butyric acid.		2.2110butyrate ester;
C-nitro compound
1-(4-nitrophenyl)piperazine
1-(4-nitrophenyl)piperazine: structure in first source		2.2110
schizandrin b
schizandrin B: a phytogenic antineoplastic agent with anti-inflammatory activity; isolated from Schisandra plant		3.1710
wortmannin
[no description available]		3.1710acetate ester;
cyclic ketone;
delta-lactone;
organic heteropentacyclic compound		anticoronaviral agent;
antineoplastic agent;
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector;
Penicillium metabolite;
radiosensitizing agent
nu 6027
[no description available]		3.1710
ku 55933
2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one: specific inhibitor of the ataxia-telangiectasia mutated kinase ATM; structure in first source		3.1710
nitrofurantoin
Nitrofurantoin: A urinary anti-infective agent effective against most gram-positive and gram-negative organisms. Although sulfonamides and antibiotics are usually the agents of choice for urinary tract infections, nitrofurantoin is widely used for prophylaxis and long-term suppression.. nitrofurantoin : An imidazolidine-2,4-dione that is hydantoin substituted at position 1 by a [(5-nitro-2-furyl)methylene]amino group. An antibiotic that damages bacterial DNA.		2.2110imidazolidine-2,4-dione;
nitrofuran antibiotic;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic		antibacterial drug;
antiinfective agent;
hepatotoxic agent
ic 86621
1-(2-hydroxy-4-morpholin-4-ylphenyl)ethanone: a DNA-dependent protein kinase inhibitor		3.1710aromatic ketone
nu 7441
8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one: structure in first source		3.1710dibenzothiophenes
ku-0060648
[no description available]		3.1710dibenzothiophenes
ve 821
3-amino-6-(4-(methylsulfonyl)phenyl)-N-phenylpyrazine-2-carboxamide: an antineoplastic agent; structure in first source		3.1710aromatic amide
ConditionIndicatedRelationship StrengthStudiesTrials
Benign Neoplasms
[description not available]		02.9910
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.9910
Congenital Zika Syndrome
[description not available]		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.2510
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.2510
Cell Transformation, Neoplastic
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.		02.1510
Cancer of Colon
[description not available]		02.0610
Metastase
[description not available]		02.0610
Cancer of Prostate
[description not available]		02.0610
Colonic Neoplasms
Tumors or cancer of the COLON.		02.0610
Neoplasm Metastasis
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.		02.0610
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.0610